Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
100
2022
966
7.310
 Why?
Lung Neoplasms
91
2023
2159
5.690
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
959
4.510
 Why?
Radiosurgery
44
2022
299
4.250
 Why?
Cranial Irradiation
20
2022
66
2.850
 Why?
Small Cell Lung Carcinoma
11
2023
77
2.750
 Why?
Combined Modality Therapy
62
2022
1117
1.320
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1356
1.300
 Why?
Radiation Pneumonitis
5
2021
24
1.280
 Why?
Radiotherapy, Intensity-Modulated
9
2018
124
1.250
 Why?
Practice Guidelines as Topic
13
2021
1381
1.210
 Why?
Carcinoma, Small Cell
8
2007
158
1.180
 Why?
Neoplasm Staging
39
2020
1162
1.160
 Why?
Radiotherapy Dosage
39
2023
243
1.080
 Why?
Chemoradiotherapy
8
2020
187
1.060
 Why?
Brachytherapy
12
2017
100
0.980
 Why?
Neoplasm Recurrence, Local
21
2017
850
0.970
 Why?
Glioblastoma
18
2016
250
0.960
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
117
0.930
 Why?
Radiation Oncology
12
2022
75
0.900
 Why?
Liver Neoplasms
8
2009
504
0.850
 Why?
Aged
102
2020
18969
0.830
 Why?
Glioma
15
2015
285
0.820
 Why?
Adenocarcinoma
13
2022
787
0.800
 Why?
Humans
221
2023
114045
0.780
 Why?
Middle Aged
118
2020
26605
0.770
 Why?
Prognosis
45
2022
3315
0.760
 Why?
Esophageal Neoplasms
9
2008
270
0.750
 Why?
Survival Rate
31
2018
1638
0.750
 Why?
Clinical Trials as Topic
18
2018
926
0.700
 Why?
Radiotherapy, Conformal
8
2017
68
0.690
 Why?
Radiotherapy
14
2017
175
0.670
 Why?
Radiotherapy, Adjuvant
16
2022
182
0.660
 Why?
Neurosurgeons
1
2019
13
0.640
 Why?
Dacarbazine
9
2016
99
0.640
 Why?
Evidence-Based Medicine
10
2021
662
0.630
 Why?
Four-Dimensional Computed Tomography
6
2021
25
0.610
 Why?
Male
128
2022
55396
0.600
 Why?
Aged, 80 and over
45
2020
6306
0.590
 Why?
Female
131
2020
59324
0.580
 Why?
Oncologists
1
2018
30
0.580
 Why?
Patient Selection
10
2019
629
0.570
 Why?
Clinical Decision-Making
3
2021
268
0.570
 Why?
Carcinoma, Squamous Cell
10
2017
577
0.550
 Why?
Cisplatin
18
2021
262
0.550
 Why?
Antineoplastic Agents
20
2017
1875
0.530
 Why?
Physician's Role
1
2018
192
0.520
 Why?
Adult
90
2020
30375
0.510
 Why?
Antineoplastic Agents, Alkylating
8
2016
68
0.510
 Why?
Induction Chemotherapy
2
2013
56
0.480
 Why?
Treatment Outcome
36
2021
9049
0.460
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
224
0.440
 Why?
Survival Analysis
24
2020
1206
0.440
 Why?
Physician-Patient Relations
1
2018
459
0.440
 Why?
Etoposide
12
2021
149
0.410
 Why?
Retrospective Studies
40
2022
12521
0.400
 Why?
Pneumonectomy
2
2015
121
0.390
 Why?
Pro-Opiomelanocortin
7
1989
17
0.390
 Why?
Astrocytoma
9
2014
106
0.370
 Why?
Melanoma
5
2018
620
0.350
 Why?
Societies, Medical
7
2021
655
0.350
 Why?
Protein Kinase Inhibitors
4
2021
784
0.350
 Why?
Medical Oncology
7
2021
229
0.330
 Why?
Guidelines as Topic
2
2020
241
0.330
 Why?
Whole-Body Irradiation
1
2009
72
0.330
 Why?
Chemotherapy, Adjuvant
12
2017
332
0.330
 Why?
Pulmonary Ventilation
4
2021
72
0.330
 Why?
Guideline Adherence
4
2018
489
0.330
 Why?
Breast Neoplasms
9
2020
1846
0.330
 Why?
ErbB Receptors
8
2022
554
0.320
 Why?
Lung
9
2021
3521
0.320
 Why?
Karnofsky Performance Status
11
2020
36
0.320
 Why?
Disease Progression
13
2018
2371
0.310
 Why?
Quinazolines
6
2014
240
0.310
 Why?
Dose-Response Relationship, Radiation
11
2019
127
0.300
 Why?
Iodine Radioisotopes
6
2006
126
0.300
 Why?
Neoplasm Metastasis
8
2019
521
0.300
 Why?
Follow-Up Studies
22
2018
4392
0.300
 Why?
Re-Irradiation
2
2018
8
0.290
 Why?
Radiopharmaceuticals
5
2014
158
0.290
 Why?
Controlled Clinical Trials as Topic
1
2007
27
0.290
 Why?
Anticonvulsants
2
2019
178
0.280
 Why?
Biomarkers, Tumor
6
2021
1032
0.280
 Why?
Tumor Burden
9
2017
258
0.270
 Why?
Tomography, X-Ray Computed
10
2018
2272
0.270
 Why?
Prospective Studies
22
2018
6195
0.270
 Why?
Paclitaxel
5
2011
190
0.260
 Why?
Proto-Oncogene Proteins B-raf
2
2017
191
0.250
 Why?
Spinal Cord
4
2018
344
0.240
 Why?
Carcinoma, Hepatocellular
2
2005
210
0.240
 Why?
Magnetic Resonance Imaging
9
2019
3039
0.240
 Why?
Steroids
2
2019
143
0.230
 Why?
Central Nervous System
2
2017
230
0.230
 Why?
Taxoids
5
2015
93
0.230
 Why?
Carcinoma
1
2006
198
0.230
 Why?
Lymphatic Metastasis
3
2017
275
0.230
 Why?
Carcinoma, Renal Cell
3
2018
168
0.220
 Why?
Gastrointestinal Neoplasms
3
2019
59
0.220
 Why?
Randomized Controlled Trials as Topic
7
2021
1204
0.210
 Why?
Neoplasms
6
2020
2086
0.200
 Why?
Radiography
8
2014
803
0.200
 Why?
Necrosis
3
2019
209
0.200
 Why?
Positron Emission Tomography Computed Tomography
2
2020
67
0.200
 Why?
Medical Illustration
2
2012
7
0.190
 Why?
Organs at Risk
2
2012
30
0.190
 Why?
Ribs
2
2012
29
0.190
 Why?
Brachial Plexus
2
2012
28
0.190
 Why?
Mutation
4
2021
3338
0.180
 Why?
Professional Staff Committees
4
2001
14
0.180
 Why?
Esophagectomy
1
2002
110
0.180
 Why?
Oligodendroglioma
4
2014
15
0.180
 Why?
Testicular Neoplasms
1
2022
96
0.180
 Why?
Research Design
7
2018
919
0.180
 Why?
Proportional Hazards Models
8
2020
1078
0.170
 Why?
Peptide Fragments
4
1989
665
0.170
 Why?
Time Factors
10
2019
6077
0.170
 Why?
Thymus Neoplasms
2
2017
20
0.170
 Why?
Thymoma
2
2017
29
0.170
 Why?
Esophagus
2
2012
224
0.170
 Why?
Consolidation Chemotherapy
1
2019
9
0.160
 Why?
Metalloporphyrins
3
2011
103
0.160
 Why?
Congresses as Topic
2
2019
193
0.160
 Why?
Maximum Tolerated Dose
6
2010
183
0.160
 Why?
Radiation Injuries
5
2015
128
0.160
 Why?
Meningeal Neoplasms
3
2017
86
0.160
 Why?
Watchful Waiting
1
2019
54
0.160
 Why?
Expert Testimony
1
2019
36
0.160
 Why?
Aquaporin 4
1
2019
86
0.150
 Why?
Cognition
4
2013
990
0.150
 Why?
Gray Matter
1
2019
67
0.150
 Why?
Quality of Life
5
2013
2343
0.150
 Why?
CTLA-4 Antigen
1
2018
76
0.150
 Why?
Spinal Neoplasms
1
2018
26
0.150
 Why?
Intracranial Arteriovenous Malformations
2
1995
51
0.150
 Why?
Kidney Neoplasms
3
2018
324
0.150
 Why?
Intersectoral Collaboration
1
2018
55
0.140
 Why?
Receptor, ErbB-2
5
2020
300
0.140
 Why?
Carboplatin
4
2011
135
0.140
 Why?
Endpoint Determination
1
2018
68
0.140
 Why?
Professional Competence
1
2018
81
0.140
 Why?
Brain
5
2019
2355
0.140
 Why?
Pituitary Neoplasms
5
1994
156
0.140
 Why?
Treatment Failure
5
2014
330
0.140
 Why?
Mortality
1
2019
283
0.140
 Why?
Antineoplastic Agents, Immunological
1
2019
152
0.140
 Why?
Decision Trees
1
1997
82
0.140
 Why?
Genes, ras
1
2017
91
0.140
 Why?
Cohort Studies
7
2019
4883
0.140
 Why?
Triazines
2
2009
36
0.140
 Why?
Proto-Oncogene Proteins c-kit
1
2017
63
0.140
 Why?
Interdisciplinary Communication
1
2018
183
0.140
 Why?
Fluorouracil
6
2004
152
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2018
193
0.130
 Why?
Salvage Therapy
4
2017
127
0.130
 Why?
United States
13
2022
12137
0.130
 Why?
Age Factors
8
2017
2885
0.130
 Why?
Antibodies
1
2018
365
0.130
 Why?
Hemangioma, Cavernous
2
1993
14
0.130
 Why?
Patient Preference
1
2018
164
0.130
 Why?
Pulmonary Atelectasis
1
2015
11
0.130
 Why?
Accreditation
2
2013
76
0.130
 Why?
Adrenal Cortex Hormones
1
2019
493
0.130
 Why?
Postoperative Care
1
2017
223
0.120
 Why?
Radiation-Sensitizing Agents
5
2009
38
0.120
 Why?
Medically Underserved Area
1
2016
80
0.120
 Why?
Central Nervous System Neoplasms
1
2017
125
0.120
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
98
0.120
 Why?
Antineoplastic Agents, Phytogenic
2
2006
181
0.120
 Why?
Adolescent
22
2017
17800
0.120
 Why?
Risk Assessment
3
2021
2958
0.120
 Why?
Triple Negative Breast Neoplasms
1
2017
157
0.120
 Why?
Carmustine
7
2010
47
0.110
 Why?
Cerebellar Neoplasms
2
1996
130
0.110
 Why?
Camptothecin
2
2011
96
0.110
 Why?
Perfusion Imaging
1
2014
51
0.110
 Why?
Analysis of Variance
5
2014
1218
0.110
 Why?
Fibrosarcoma
1
1993
20
0.110
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
16
0.110
 Why?
Pyrazoles
2
2014
361
0.110
 Why?
Medulloblastoma
2
1996
172
0.110
 Why?
Receptors, Progesterone
4
2020
319
0.110
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1145
0.110
 Why?
Contraindications
2
2008
84
0.110
 Why?
Pyridines
2
2014
419
0.110
 Why?
Nelson Syndrome
4
1987
4
0.110
 Why?
Respiratory Function Tests
1
2015
522
0.110
 Why?
Kaplan-Meier Estimate
5
2019
813
0.110
 Why?
Disease-Free Survival
6
2014
618
0.110
 Why?
Pancreatic Neoplasms
1
2000
721
0.100
 Why?
beta-Endorphin
3
1989
7
0.100
 Why?
Young Adult
8
2017
10444
0.100
 Why?
Radiotherapy, High-Energy
4
2000
12
0.100
 Why?
Bone Neoplasms
3
2007
191
0.100
 Why?
Particle Accelerators
1
1991
9
0.100
 Why?
Adrenocorticotropic Hormone
3
1989
128
0.090
 Why?
Radiation Protection
2
2009
34
0.090
 Why?
Hyperthermia, Induced
1
1992
66
0.090
 Why?
Forced Expiratory Volume
2
2015
471
0.090
 Why?
Databases, Factual
5
2017
1125
0.090
 Why?
Quality Assurance, Health Care
3
2009
308
0.090
 Why?
Risk Factors
7
2021
8614
0.090
 Why?
Bevacizumab
3
2015
114
0.090
 Why?
Technology, Radiologic
1
2010
6
0.090
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.090
 Why?
Severity of Illness Index
2
2008
2537
0.090
 Why?
Spine
1
1991
136
0.090
 Why?
Palliative Care
5
2018
641
0.080
 Why?
MEDLINE
1
2009
22
0.080
 Why?
Adenoma
4
1994
187
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
59
0.080
 Why?
Multivariate Analysis
6
2020
1422
0.080
 Why?
Education, Medical, Graduate
1
2013
366
0.080
 Why?
Neurosurgery
1
2009
26
0.080
 Why?
Catheter Ablation
1
2012
287
0.080
 Why?
Adrenal Medulla
1
1989
7
0.080
 Why?
Liver
2
2008
1633
0.080
 Why?
Neurotensin
1
1989
11
0.080
 Why?
Drug Therapy
1
2009
74
0.080
 Why?
Piperidines
1
2010
159
0.080
 Why?
Ependymoma
2
2009
152
0.080
 Why?
Meta-Analysis as Topic
1
2009
156
0.080
 Why?
Fractures, Spontaneous
1
1988
13
0.080
 Why?
Imaging, Three-Dimensional
2
2010
511
0.080
 Why?
Surveys and Questionnaires
2
2018
4595
0.080
 Why?
Esophageal Fistula
2
2000
17
0.080
 Why?
Radionuclide Imaging
1
2008
115
0.080
 Why?
Equipment Failure Analysis
1
2009
132
0.080
 Why?
Pheochromocytoma
1
1989
54
0.080
 Why?
Respiratory Mechanics
1
2008
56
0.080
 Why?
Lymph Node Excision
1
2009
140
0.080
 Why?
Femoral Fractures
1
1988
64
0.080
 Why?
Positron-Emission Tomography
2
2008
260
0.080
 Why?
Kidney
2
2005
1182
0.080
 Why?
Craniopharyngioma
1
2009
65
0.080
 Why?
Humeral Fractures
1
1988
46
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
81
0.070
 Why?
Chromatography, Gel
4
1989
122
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
907
0.070
 Why?
Clinical Competence
1
2013
882
0.070
 Why?
Seizures
1
2009
337
0.070
 Why?
Statistics, Nonparametric
2
2018
384
0.070
 Why?
Biomedical Research
2
2009
582
0.070
 Why?
Radioimmunoassay
4
1989
161
0.070
 Why?
Uterine Cervical Neoplasms
1
1989
213
0.070
 Why?
Vascular Diseases
1
2009
233
0.060
 Why?
Neoplasm Grading
2
2020
241
0.060
 Why?
Whole Body Imaging
1
2006
19
0.060
 Why?
Genetic Markers
2
2017
320
0.060
 Why?
Immunotherapy
2
2022
473
0.060
 Why?
Hepatitis B, Chronic
1
2005
18
0.060
 Why?
Linear Models
3
2017
768
0.060
 Why?
Diagnostic Imaging
3
2009
278
0.060
 Why?
Drug Administration Schedule
3
2014
714
0.060
 Why?
Anticoagulants
1
2009
547
0.060
 Why?
Peptides
3
1985
847
0.060
 Why?
Hemoglobins
1
2007
308
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
496
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Physicians
1
2013
765
0.060
 Why?
Delivery of Health Care
1
2012
828
0.060
 Why?
Gene Rearrangement
2
2018
135
0.060
 Why?
Antiemetics
1
2005
32
0.060
 Why?
Databases as Topic
1
2005
63
0.060
 Why?
Feasibility Studies
3
2011
735
0.060
 Why?
Practice Patterns, Physicians'
1
2013
1175
0.060
 Why?
Consensus
2
2021
532
0.060
 Why?
Pituitary Hormones
1
1984
16
0.060
 Why?
Organ Size
1
2005
434
0.060
 Why?
Body Fluids
1
1985
58
0.060
 Why?
Cognition Disorders
2
2010
476
0.060
 Why?
Dexamethasone
3
2012
316
0.060
 Why?
Retreatment
3
2012
67
0.060
 Why?
Age Distribution
1
2005
341
0.060
 Why?
Sex Distribution
1
2005
336
0.060
 Why?
Internship and Residency
1
2013
920
0.060
 Why?
Liver Cirrhosis
1
2005
227
0.060
 Why?
Regression Analysis
2
2017
945
0.060
 Why?
Erlotinib Hydrochloride
2
2014
64
0.060
 Why?
Hepatitis C, Chronic
1
2005
150
0.050
 Why?
Preoperative Care
1
2005
319
0.050
 Why?
Propionates
1
2003
34
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
239
0.050
 Why?
Aniline Compounds
1
2003
70
0.050
 Why?
Chromatography, Affinity
3
1989
80
0.050
 Why?
Societies
1
2022
36
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
82
0.050
 Why?
Algorithms
2
2017
1469
0.050
 Why?
Pterygium
1
2000
4
0.050
 Why?
Reproducibility of Results
2
2015
2764
0.050
 Why?
Organizational Objectives
4
2001
66
0.040
 Why?
B7-H1 Antigen
1
2022
137
0.040
 Why?
Esophagoscopy
1
2002
181
0.040
 Why?
Vincristine
2
2010
98
0.040
 Why?
Ontario
2
2017
77
0.040
 Why?
Neurologic Examination
1
2000
113
0.040
 Why?
BRCA1 Protein
1
2020
56
0.040
 Why?
Neuropsychological Tests
3
2013
926
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
17
0.040
 Why?
Spinal Cord Neoplasms
1
1999
36
0.040
 Why?
Receptors, Estrogen
2
2013
371
0.040
 Why?
Carcinoma, Large Cell
1
1999
14
0.040
 Why?
Reoperation
2
2012
513
0.040
 Why?
Medical Records
2
2010
153
0.040
 Why?
Liver Transplantation
1
2005
695
0.040
 Why?
Child, Preschool
7
2009
9114
0.040
 Why?
Urinary Bladder Neoplasms
1
2001
196
0.040
 Why?
Estrogens
1
2020
312
0.040
 Why?
Colorado
3
2014
4090
0.040
 Why?
Thoracic Vertebrae
1
2018
68
0.040
 Why?
Iridium Radioisotopes
1
1997
4
0.040
 Why?
Epidemiologic Methods
1
2017
72
0.030
 Why?
Aziridines
2
1994
4
0.030
 Why?
Precision Medicine
1
2020
335
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
45
0.030
 Why?
Skin Neoplasms
2
2017
754
0.030
 Why?
Molecular Weight
2
1989
328
0.030
 Why?
Propensity Score
1
2018
225
0.030
 Why?
Biopsy, Needle
1
2017
180
0.030
 Why?
Memory Disorders
2
2010
153
0.030
 Why?
Esophagitis
2
2009
65
0.030
 Why?
Benzoquinones
2
1994
44
0.030
 Why?
Respiration
1
2017
180
0.030
 Why?
Neutropenia
2
2009
123
0.030
 Why?
Sex Factors
2
2014
1706
0.030
 Why?
Supratentorial Neoplasms
1
1996
17
0.030
 Why?
Odds Ratio
1
1999
951
0.030
 Why?
Heart
1
2020
613
0.030
 Why?
Pilot Projects
3
2015
1360
0.030
 Why?
Meningioma
1
1997
76
0.030
 Why?
Estrogen Receptor alpha
1
2017
121
0.030
 Why?
Cerebral Angiography
1
1995
108
0.030
 Why?
Forecasting
3
2001
331
0.030
 Why?
Child
9
2009
18401
0.030
 Why?
Myocardium
1
2020
911
0.030
 Why?
Marital Status
1
2014
41
0.030
 Why?
Patient Safety
1
2017
273
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
9
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Nuclear Medicine
1
2014
7
0.030
 Why?
Developing Countries
1
2016
231
0.030
 Why?
Vital Capacity
1
2015
254
0.030
 Why?
Molecular Targeted Therapy
1
2017
347
0.030
 Why?
Texas
1
2014
188
0.030
 Why?
Nervous System Diseases
1
1997
254
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Cobalt Radioisotopes
1
1993
6
0.030
 Why?
Prostatic Neoplasms
1
2001
913
0.030
 Why?
SEER Program
1
2014
195
0.030
 Why?
Vimentin
1
1993
58
0.030
 Why?
Spatial Analysis
1
2013
20
0.030
 Why?
Radiodermatitis
1
1993
7
0.030
 Why?
Cerebral Cortex
1
1996
380
0.030
 Why?
Radiometry
1
2013
41
0.030
 Why?
Observer Variation
1
2014
298
0.030
 Why?
Monte Carlo Method
1
2013
136
0.030
 Why?
Scalp
1
1993
29
0.030
 Why?
Time
1
2013
70
0.030
 Why?
Protein-Tyrosine Kinases
1
2016
393
0.030
 Why?
Mitosis
1
1993
164
0.030
 Why?
Medical Errors
1
2013
86
0.030
 Why?
Ascorbic Acid
1
1993
110
0.030
 Why?
Radiation Dosage
1
2013
133
0.030
 Why?
Remission Induction
2
2008
233
0.020
 Why?
Radiology
1
2014
137
0.020
 Why?
Disease Management
1
2016
556
0.020
 Why?
Longitudinal Studies
1
2018
2384
0.020
 Why?
Diagnosis, Differential
1
2015
1331
0.020
 Why?
International Agencies
1
2011
29
0.020
 Why?
Sensitivity and Specificity
1
2015
1690
0.020
 Why?
Electrons
1
1991
71
0.020
 Why?
Breast Neoplasms, Male
1
2011
28
0.020
 Why?
Fibrosis
1
2013
452
0.020
 Why?
Bronchography
1
2010
9
0.020
 Why?
Infusions, Intravenous
2
2004
370
0.020
 Why?
Cell Nucleus
1
1993
552
0.020
 Why?
Procarbazine
1
1990
8
0.020
 Why?
Lomustine
1
1990
14
0.020
 Why?
Chromatin
1
1993
425
0.020
 Why?
Prevalence
1
2016
2247
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Incidence
1
2016
2314
0.020
 Why?
Smoking
1
2017
1382
0.020
 Why?
Neoplasm, Residual
1
2010
104
0.020
 Why?
Selection Bias
1
2009
33
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
5
0.020
 Why?
Hypophysectomy
1
1989
15
0.020
 Why?
Quality Control
1
2010
143
0.020
 Why?
Immunohistochemistry
1
1993
1624
0.020
 Why?
Platinum
1
2009
38
0.020
 Why?
Certification
1
2010
84
0.020
 Why?
Bronchi
1
2010
223
0.020
 Why?
Adrenal Cortex
1
1989
32
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
1880
0.020
 Why?
Infant
4
1999
7943
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
12
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
11
0.020
 Why?
Liver Regeneration
1
2008
29
0.020
 Why?
Prostheses and Implants
1
2010
135
0.020
 Why?
Anti-Inflammatory Agents
1
2012
445
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Endorphins
2
1985
7
0.020
 Why?
Administration, Oral
1
2010
725
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2090
0.020
 Why?
Motion
1
2008
92
0.020
 Why?
International Cooperation
1
2008
169
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
53
0.020
 Why?
Epinephrine
1
1989
163
0.020
 Why?
Reference Values
1
1989
739
0.020
 Why?
Mental Status Schedule
1
2007
33
0.020
 Why?
Predictive Value of Tests
2
2008
1791
0.020
 Why?
Creatinine
1
1989
424
0.020
 Why?
Rectal Neoplasms
1
2008
122
0.020
 Why?
Bleomycin
1
2009
228
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
465
0.020
 Why?
California
1
2008
351
0.020
 Why?
DNA Repair
1
2008
184
0.020
 Why?
Southwestern United States
1
2006
90
0.020
 Why?
Methadone
1
1987
77
0.020
 Why?
Hydrocephalus
1
1987
83
0.020
 Why?
Glucocorticoids
1
2010
526
0.020
 Why?
Neovascularization, Pathologic
1
2008
280
0.020
 Why?
Chromium Compounds
1
2006
2
0.020
 Why?
Sodium Iodide
1
2006
3
0.020
 Why?
Pleural Effusion, Malignant
1
2006
8
0.020
 Why?
Polycythemia Vera
1
2006
12
0.020
 Why?
Hyperthyroidism
1
2006
26
0.020
 Why?
Patient Isolation
1
2006
18
0.020
 Why?
Ascites
1
2006
32
0.020
 Why?
Yttrium Radioisotopes
1
2006
51
0.020
 Why?
DNA Damage
1
2008
351
0.020
 Why?
Patient Education as Topic
1
2010
666
0.020
 Why?
Lymphoma, Non-Hodgkin
1
2006
70
0.020
 Why?
Organophosphorus Compounds
1
2006
72
0.020
 Why?
Chromatography
1
1985
23
0.020
 Why?
Phosphates
1
2006
155
0.020
 Why?
Concanavalin A
1
1985
74
0.020
 Why?
Organometallic Compounds
1
2006
98
0.020
 Why?
Occipital Lobe
1
2004
23
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
2
0.010
 Why?
Genomics
1
2009
631
0.010
 Why?
Biotransformation
1
1984
48
0.010
 Why?
Carbohydrate Metabolism
1
1984
48
0.010
 Why?
Brain Edema
1
2004
59
0.010
 Why?
Recurrence
2
2000
925
0.010
 Why?
Thrombocytopenia
1
2006
177
0.010
 Why?
Arginine Vasopressin
1
1984
46
0.010
 Why?
Vomiting
1
2004
122
0.010
 Why?
Bipolar Disorder
1
1985
203
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
67
0.010
 Why?
Oils
1
1983
19
0.010
 Why?
Motor Skills
1
2004
82
0.010
 Why?
Thyroid Neoplasms
1
2006
271
0.010
 Why?
Immunologic Factors
1
2003
217
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
80
0.010
 Why?
Opioid-Related Disorders
1
1987
413
0.010
 Why?
Psychometrics
1
2004
608
0.010
 Why?
Pain
1
2006
701
0.010
 Why?
Postoperative Period
1
2000
288
0.010
 Why?
Antibodies, Monoclonal
1
2006
1257
0.010
 Why?
Thorax
1
1999
41
0.010
 Why?
Apoptosis
1
2008
2349
0.010
 Why?
Michigan
1
1999
95
0.010
 Why?
Cysts
1
1999
92
0.010
 Why?
Bias
1
1999
178
0.010
 Why?
Cross-Sectional Studies
1
2007
4402
0.010
 Why?
Meninges
1
1997
29
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
27
0.010
 Why?
Biopsy
1
1999
1024
0.010
 Why?
Autoantibodies
1
1983
1347
0.010
 Why?
Decision Making
1
2001
760
0.010
 Why?
Cause of Death
1
1996
362
0.010
 Why?
Solutions
1
1993
144
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
66
0.010
 Why?
Cerebral Hemorrhage
1
1993
96
0.010
 Why?
Computer Simulation
1
1995
873
0.010
 Why?
Patient Compliance
1
1994
524
0.010
 Why?
Evaluation Studies as Topic
1
1989
167
0.000
 Why?
Double-Blind Method
1
1993
1656
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
2
0.000
 Why?
Postoperative Complications
1
1996
2122
0.000
 Why?
Lithium
1
1985
36
0.000
 Why?
Brassica
1
1983
3
0.000
 Why?
Spain
1
1983
32
0.000
 Why?
Drug Synergism
1
1984
315
0.000
 Why?
Antigen-Antibody Complex
1
1983
84
0.000
 Why?
Syndrome
1
1983
330
0.000
 Why?
In Vitro Techniques
1
1984
1003
0.000
 Why?
Sheep
1
1984
761
0.000
 Why?
Animals
1
1984
31565
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (36) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)